文献速递妇科肿瘤

卡博替尼在卵巢癌患者中的2期随机停药试验

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
PubMed 文献 · Eur J Cancer · 2017-07-26

这项2期随机停药试验纳入70例卵巢癌患者(50%为铂难治/耐药),每日口服卡博替尼100mg。第12周客观缓解率为21%,疾病控制率50%,自第1天起中位无进展生存期5.5个月;最常见3/4级不良事件为腹泻(14%)。结论认为卡博替尼在卵巢癌中显示临床活性,毒性可接受。

要点

  • 70例卵巢癌患者中50%为铂难治/耐药,每日口服卡博替尼100mg。
  • 第12周客观缓解率21%,疾病控制率50%,自第1天起中位无进展生存期5.5个月。
  • 最常见3/4级不良事件为腹泻(14%),37%患者在最初12周内需减量。

核心结论

  • 基于客观缓解率和肿瘤靶病灶退缩,卡博替尼在卵巢癌患者中显示临床活性,毒性可接受。

研究设计与样本

  • 2期随机停药试验(RDT),纳入来自九种不同肿瘤类型的队列,本报告为卵巢癌队列。
  • 卵巢癌队列共纳入70例患者,其中50%为铂难治/耐药。
  • 患者每日口服卡博替尼100mg;第12周根据实体瘤疗效评价标准达疾病稳定的患者随机分配至卡博替尼或安慰剂组。
  • 主要终点为第12周客观缓解率和随机分配后的无进展生存期。
  • 试验注册于ClinicalTrial.gov(NCT00940225)。

主要发现

  • 全部患者自第1天起中位无进展生存期为5.5个月。
  • 第12周客观缓解率为21%;1例患者达完全缓解,14例(20%)达确认的部分缓解。
  • 第12周总体疾病控制率(完全缓解+部分缓解+疾病稳定)为50%。
  • 研究期间,有至少1次基线后扫描的患者中70%出现肿瘤退缩,随机分配提前终止。
  • 随机分配至卡博替尼的疾病稳定患者,随机分配后无进展生存期为5.9个月。

局限性

  • 随机分配提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cabozantinib (XL184), an orally bioavailable inhibitor of vascular endothelial growth factor receptor 2 and MET, was assessed in a cohort of ovarian carcinoma patients as part of a phase 2 randomised discontinuation trial (RDT) with cohorts from nine different tumour types. PATIENTS AND METHODS: Patients received 100-mg cabozantinib daily. Those with stable disease (SD) per Response Evaluation Criteria in Solid Tumors at week 12 were randomised to cabozantinib or placebo. Primary end-points were objective response rate (ORR) at week 12 and progression-free survival (PFS) after random assignment. RESULTS: Seventy patients with ovarian carcinoma, 50% of whom were platinum refractory/resistant, were enrolled in this RDT. Median PFS from day 1 was 5.5 months for all patients. The ORR at week 12 was 21%; one patient achieved a complete response (CR), and 14 patients (20%) achieved a confirmed partial response (PR). The overall disease control rate (CR + PR + SD) at week 12 was 50%. Throughout the study, 70% of the patients with ≥1 postbaseline scan had tumour regression, and randomisation was discontinued early. For patients with SD randomised to cabozantinib, PFS was 5.9 months after randomisation. The most common grade 3/4 adverse events were diarrhoea (14%), palmar-plantar erythrodysesthesia syndrome (6%), asthenia (6%), hypertension (6%) and neutropenia (6%). Dose reductions were required in 37% of the patients during the first 12 weeks. CONCLUSION: Cabozantinib demonstrates clinical activity, with acceptable toxicities, in patients with ovarian carcinoma based on ORR and regression of tumour target lesions. REGISTRATION: This trial is registered at ClinicalTrial.gov (NCT00940225).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vergote IB, Smith DC, Berger R, et al. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. Eur J Cancer. 2017. PMID: 28755607. doi:10.1016/j.ejca.2017.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。